The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Timeline
X Demographics
Mendeley readers
Attention Score in Context
Title |
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma
|
---|---|
Published in |
Frontiers in oncology, June 2023
|
DOI | 10.3389/fonc.2023.1176448 |
Pubmed ID | |
Authors |
Howard Fine, Tony Reid, Scott Caroen, Bryan Oronsky, Nacer Abrouk, Nicholas Butowski |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 20% |
Unknown | 4 | 80% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 5 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 2 | 40% |
Student > Ph. D. Student | 1 | 20% |
Unknown | 2 | 40% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 2 | 40% |
Biochemistry, Genetics and Molecular Biology | 1 | 20% |
Unknown | 2 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 August 2023.
All research outputs
#15,346,946
of 26,515,106 outputs
Outputs from Frontiers in oncology
#4,116
of 23,233 outputs
Outputs of similar age
#164,816
of 397,536 outputs
Outputs of similar age from Frontiers in oncology
#137
of 1,139 outputs
Altmetric has tracked 26,515,106 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 23,233 research outputs from this source. They receive a mean Attention Score of 3.2. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 397,536 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.
We're also able to compare this research output to 1,139 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.